TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference

Stock News

昨天

TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1106629682"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106629682\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106629682?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106629682","market":"fut","top_or_hot":-1,"title":"TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-25 22:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"開拓藥業-B","start_time":0,"source_url":"","article_id":"1106629682","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106629682","pubTimestamp":1774449860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","159992":"创新药","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","06978":"永泰生物-B","02410":"同源康医药-B","BK1574":"生物医药B类股"},"translate_title":"TYK MEDICINES-B将在2026年AACR会议上展示五个新药项目的研究结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"159992":1,"09939":1,"02410":1,"06978":1},"content_text":"TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}